logo-loader

New Age Beverages shares sink on profit-taking after big run-up

Last updated: 14:44 21 Sep 2018 EDT, First published: 14:14 21 Sep 2018 EDT

drink in a festive glass
New Age's debut of a new line of CBD-infused beverages ramped up rumors that Coca-Cola might be a suitor

Shares of New Age Beverages Corp (NASDAQ:NBEV) sank Friday after investors took profits and cashed in on the more than five-fold rise in the Denver-based beverage company’s stock over the last week.

By Friday afternoon, New Age shares had slipped nearly 15% to US$6.68, which marked a sharp reversal from the stock’s dramatic climb, which saw its shares shoot up to an intraday high of US$9.99 earlier in the day Friday from a low of US$1.69 on Monday.

Shares of New Age Beverages have been on a tear since rumors first emerged that the beverages company might be acquired by The Coca-Cola Co (NYSE:KO).

New Age’s stock also got a boost Thursday, closing up 38% at US$7.85, after it said it was debuting a new line of CBD-infused beverages at the North American Convenience Store Show next month.

Read: New Age Beverages stock flies on plans to showcase CBD-infused drinks in Las Vegas

The company said that its portfolio of CBD-infused beverages would be on display at the North American Convenience Store show (NACS) at the Las Vegas Convention Center on October 7 through October 10.

CBD, which does not produce a high for the user, has been used for medical purposes, including easing inflammation, pain and nausea.

The maker of Marley Cold Brew and Marley Mellow Mood said it began testing a CBD-infused beverage earlier this year in its home market in Colorado.

It said it was now taking the “learnings” it gained in product formulation, taste, efficacy and dosing to create a portfolio of CBD-infused beverages.

The company’s proposed introduction of a line of CBD-infused beverages ramped up talk that Coca-Cola might come along as its suitor.

At the start of the week, Coca-Cola said it is “closely watching” the growth of CBD, a non-psychoactive component in marijuana, as an ingredient in what it called functional wellness beverages.

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

12 hours, 37 minutes ago